BR112012024585A2 - inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas - Google Patents

inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas

Info

Publication number
BR112012024585A2
BR112012024585A2 BR112012024585A BR112012024585A BR112012024585A2 BR 112012024585 A2 BR112012024585 A2 BR 112012024585A2 BR 112012024585 A BR112012024585 A BR 112012024585A BR 112012024585 A BR112012024585 A BR 112012024585A BR 112012024585 A2 BR112012024585 A2 BR 112012024585A2
Authority
BR
Brazil
Prior art keywords
chronic active
cell
signaling
receptor signaling
cell receptor
Prior art date
Application number
BR112012024585A
Other languages
English (en)
Inventor
Frank P Stegmeier
Markus Warmuth
Walter Schuler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012024585A2 publication Critical patent/BR112012024585A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas a presente invenção demonstra que a sinalização bcr ativa crônica através de cd79a/b confere uma forte dependência sobre a sinalização de pkcb cinase a jusante. portanto, é aqui fornecido um método para a inibição do crescimento de linfoma de células b tendo a sinalização de receptor de células b ativa crônica , ou inibição do crescimento de cânceres com lesões moleculares que conduzem à sinalização bcr ativa crônica, através da administração a um paciente com necessidade de tal tratamento de uma quantidade terapeuticamente eficaz de um inibidor de pkc ou um uso de inibidor de pkc para inibir o crescimento de lifoma de células b tendo a sinalização de receptor de células b ativa crônica ou inibir o crescimento de cânceres com lesões moleculares que levam à sinalização bcr ativa crônica.
BR112012024585A 2010-03-30 2011-03-28 inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas BR112012024585A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31901310P 2010-03-30 2010-03-30
US201061425525P 2010-12-21 2010-12-21
PCT/EP2011/054709 WO2011120911A1 (en) 2010-03-30 2011-03-28 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling

Publications (1)

Publication Number Publication Date
BR112012024585A2 true BR112012024585A2 (pt) 2016-05-31

Family

ID=44710357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024585A BR112012024585A2 (pt) 2010-03-30 2011-03-28 inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas

Country Status (12)

Country Link
US (1) US8748428B2 (pt)
EP (1) EP2552428A1 (pt)
JP (1) JP2013523678A (pt)
KR (2) KR101461767B1 (pt)
CN (1) CN102821759A (pt)
AR (1) AR080737A1 (pt)
AU (1) AU2011234644B2 (pt)
BR (1) BR112012024585A2 (pt)
CA (1) CA2795456A1 (pt)
MX (1) MX2012011341A (pt)
RU (1) RU2012146083A (pt)
WO (1) WO2011120911A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US10155024B2 (en) 2014-03-28 2018-12-18 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CA3030429A1 (en) 2016-07-14 2018-01-18 Mingsight Pharmaceuticals, Inc. Treatment of cancer
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
PE49195A1 (es) 1993-12-07 1996-01-06 Lilly Co Eli Inhibidor de proteinquinasa
JP3998261B2 (ja) 1993-12-23 2007-10-24 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃ阻害剤
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
KR20080014934A (ko) * 2000-11-07 2008-02-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
ES2485841T3 (es) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US20060281787A1 (en) 2003-10-24 2006-12-14 Graff Jeremy R Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
EP1871377A1 (en) 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PL1904482T3 (pl) 2005-07-11 2011-06-30 Novartis Ag Pochodne indolilomaleimidowe
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
EP1954699B1 (en) 2005-11-22 2012-09-19 Kudos Pharmaceuticals Ltd PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
MX2009001946A (es) 2006-08-23 2009-03-05 Kudos Pharm Ltd Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor.
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CN101939006B (zh) 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors

Also Published As

Publication number Publication date
KR20120133389A (ko) 2012-12-10
MX2012011341A (es) 2012-11-12
US8748428B2 (en) 2014-06-10
CA2795456A1 (en) 2011-10-06
AR080737A1 (es) 2012-05-02
EP2552428A1 (en) 2013-02-06
KR101461767B1 (ko) 2014-11-13
RU2012146083A (ru) 2014-05-10
AU2011234644B2 (en) 2014-07-17
AU2011234644A1 (en) 2012-10-11
KR20140107685A (ko) 2014-09-04
WO2011120911A1 (en) 2011-10-06
CN102821759A (zh) 2012-12-12
US20110245256A1 (en) 2011-10-06
JP2013523678A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
BR112012024585A2 (pt) inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
SV2009003283A (es) Inhibidores de la actividad de la akt
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
ECSP099724A (es) Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer
UY31679A1 (es) Inhibidores de cinasa pim y metodos para su uso
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
MY183661A (en) Treatment of cancer with tor kinase inhibitors
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BRPI0904882B8 (pt) dispositivo de acesso cirúrgico
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
CY1123398T1 (el) Συνθεση συνδυασμου
BR112012009891A2 (pt) métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112012021334A2 (pt) material biodegradável, contendo silício, para terapia anti-inflamatória.
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]